- Sumei Slim Patch Now Covers 26 Countries and Regions -
HARBIN, China, Feb. 25 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that its wholly owned subsidiary, Harbin Tian Di Ren Medical Science and Technology Company, has expanded the sale of its Sumei Slim Patch into South Korea and Sudan. As a result, the product is now available in 26 countries and regions.
Following three months of market research, discussions and negotiations, China Sky One Medical has engaged PAX·Medicare and Lai Li Investment Company as exclusive sales agents for the Sumei Slim Patch in South Korea and Sudan, respectively. The Slim Patch has passed the necessary examinations required in both countries and will be available to consumers shortly. China Sky One Medical's international sales team, PAX-Medicare and Lai Li Investment Company, is currently developing a detailed marketing plan that includes sales projections for the Slim Patch in both South Korea and in Sudan.
The Sumei Slim Patch is a proprietary weight loss product. Its main ingredients are extracted from Chinese herbs, which are healthy, natural and free of harmful side effects. Due to its effectiveness and safety, the Sumei Slim Patch is one of China Sky One Medical's best-selling products, and has received accolades from consumers in China and in other countries.
"We are pleased to expand sales of the Sumei Slim Patch into South Korea and Sudan, which is a testament to the product's popularity and strong market potential," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "It is well known that South Koreans spend money on keeping in shape, and we expect Sumei Slim Patch to perform well in these countries and create value for both consumers and shareholders."
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its
wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio- Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .
Safe Harbor Statement
Certain of the statements made in the press release constitute
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding Su Mei Slim Patch's expansion to international market. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
For more information, please contact:
Company Contact:
China Sky One Medical, Inc.
Mr. Yu-Bo Hao, CFO
Tel: +86-451-5399-4069
Email: china_sky_one@yahoo.cn
Investor Relations Contact:
CCG Investor Relations
Mr. Crocker Coulson, President
Tel: +1-646-213-1915
Email: crocker.coulson@ccgir.com
Web: http://www.ccgirasia.com
